Details of the Drug Combination

General Information of Drug Combination (ID: DCHXTKN)

Drug Combination Name

Diamyd [3H]GABA

Indication

Disease Entry	Status	REF
.	Phase 1	[1]

Component Drugs

Diamyd DMOUGX1

[3H]GABA DMH24GL

N.A.

Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Diamyd

Disease Entry	ICD 11	Status	REF
Type-1 diabetes	5A10	Phase 3	[2]

Diamyd Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Glutamate decarboxylase 2 (GAD2)	TT7UY6K	DCE2_HUMAN	Immunomodulator	[4]
------------------------------------------------------------------------------------

Indication(s) of [3H]GABA

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[3]

References

1	FDA Drug Development and Drug Interactions
2	ClinicalTrials.gov (NCT00751842) A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT. U.S. National Institutes of Health.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5410).
4	Clinical pipeline report, company report or official report of Diamyd Medical.